For a patient with type 2 diabetes and moderate‑to‑severe diabetic retinopathy (or a baseline A1C ≥ 9 %), how does Ozempic (semaglutide) compare to Trulicity (dulaglutide) regarding glucose‑lowering efficacy, risk of early retinal worsening, and dosing recommendations?

Ozempic vs Trulicity: Comparable Efficacy and Retinal Risk

Both Ozempic (semaglutide) and Trulicity (dulaglutide) demonstrate similar glucose-lowering efficacy and carry comparable risks of early retinal worsening in patients with moderate-to-severe diabetic retinopathy or baseline A1C ≥ 9%, requiring identical ophthalmologic monitoring protocols before and during treatment intensification.

Glucose-Lowering Efficacy

Both agents achieve robust A1C reductions with minimal clinically meaningful differences:

• Semaglutide: A1C reductions of approximately 1.4-1.6% at standard doses (0.5-1.0 mg weekly) 1
• Dulaglutide: A1C reductions of approximately 1.1-1.4% at standard doses (0.75-1.5 mg weekly) 2

Real-world comparative data show semaglutide may produce modestly greater A1C reductions (approximately 0.6-0.7% additional reduction) when patients switch from dulaglutide 3. However, head-to-head outcomes trials demonstrate similar cardiovascular and renal protection between these agents 4, 5.

Risk of Early Retinal Worsening

Both semaglutide and dulaglutide carry FDA warnings for diabetic retinopathy complications in patients with pre-existing retinopathy 6. The most recent ADA guidelines (2025) explicitly state that "GLP-1 RAs including liraglutide, semaglutide, and dulaglutide have been shown to be associated with a risk of mildly worsening diabetic retinopathy in randomized trials" 7.

Key Risk Factors for Early Worsening:

The retinopathy risk is not drug-specific but mechanism-driven, related to:

• Rapid A1C reduction (>1.0% within 3-6 months) 8, 9
• Baseline A1C ≥ 9% 2
• Pre-existing moderate-to-severe diabetic retinopathy 10

The 2022 Canadian Cardiovascular Society guideline clarifies: "This increase appears to be due to the rapid and robust glucose-lowering in people with marked hyperglycemia and preexisting retinopathy—a phenomenon previously observed with insulin" 2. This is early worsening of diabetic retinopathy (EWDR), a well-recognized phenomenon with any rapid glycemic improvement.

Recent large-scale real-world data (810,390 semaglutide users) found no increased risk of proliferative diabetic retinopathy or treatment-requiring diabetic retinopathy/macular edema with semaglutide compared to dulaglutide (HR 0.53,95% CI 0.31-0.91) 11. Another study of 173,216 patients with pre-existing diabetic retinopathy showed GLP-1 RAs (including both agents) were associated with reduced progression to proliferative diabetic retinopathy (HR 0.78,95% CI 0.71-0.86) 5.

Dosing Recommendations for High-Risk Patients

Semaglutide (Ozempic):

• Start 0.25 mg weekly × 4 weeks
• Increase to 0.5 mg weekly × 4 weeks
• Titrate to 1.0 mg weekly (maximum 2.0 mg if needed) 2

Dulaglutide (Trulicity):

• Start 0.75 mg weekly (or 1.5 mg weekly)
• Can increase to 3.0 mg or 4.5 mg weekly for additional glycemic benefit 2, 6

Critical dosing principle: Slower titration reduces the rate of A1C decline, potentially mitigating EWDR risk 2.

Mandatory Ophthalmologic Protocol

Before initiating either agent in patients with A1C ≥ 9% or known diabetic retinopathy 12, 13:

1. Comprehensive dilated eye examination within 12 months prior to initiation 12, 13
2. Document retinopathy severity (none, mild, moderate, severe NPDR, or PDR) 14
3. If moderate-to-severe NPDR or PDR present: Arrange ophthalmology follow-up at 3-6 months after GLP-1 RA initiation 10, 7
4. Counsel patients that rapid glucose improvement may temporarily worsen retinopathy, but long-term glycemic control benefits outweigh this transient risk 2

Concomitant Medication Adjustments

Reduce hypoglycemia risk when starting either agent 12, 13, 6:

• Sulfonylureas: Reduce dose by 50% or discontinue
• Basal insulin: Reduce dose by 20%
• Monitor glucose closely for first 4 weeks

Common Pitfalls to Avoid

1. Avoiding GLP-1 RAs entirely in patients with retinopathy: This denies patients proven cardiovascular and renal benefits. The key is appropriate monitoring, not avoidance 2, 15.

2. Rapid dose escalation: Aggressive titration increases EWDR risk. Use the recommended gradual titration schedules 2.

3. Failing to obtain baseline eye examination: This is a guideline-mandated step before intensifying glucose-lowering therapy in high-risk patients 12, 13.

4. Assuming semaglutide has uniquely higher retinal risk: Current evidence shows the risk is class-related and mechanism-driven (rapid A1C reduction), not specific to semaglutide 7, 11, 8.

Clinical Decision Algorithm

For patients with T2DM, A1C ≥ 9%, and/or moderate-to-severe diabetic retinopathy:

→ Obtain dilated eye exam within past 12 months
→ If moderate-to-severe NPDR or PDR: Coordinate with ophthalmology before starting GLP-1 RA
→ Choose either semaglutide or dulaglutide based on:

• Dosing preference (weekly injection frequency is identical)
• Cost/insurance coverage
• Patient preference for pen device → Use slow titration schedule (4-week intervals minimum)
  → Reduce sulfonylurea/insulin doses prophylactically
  → Schedule ophthalmology follow-up at 3-6 months post-initiation
  → Monitor A1C monthly initially; avoid >1% reduction per month if possible

The choice between semaglutide and dulaglutide should be based on practical factors (cost, availability, patient preference) rather than perceived differences in retinal safety, as both carry equivalent warnings and similar real-world risk profiles when used appropriately 7, 6, 11, 5.